desipramine has been researched along with Congenital Myotonic Dystrophy in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gascon, GG | 1 |
| Staton, RD | 1 |
| Patterson, BD | 1 |
| Konewko, PJ | 1 |
| Wilson, H | 1 |
| Carlson, KM | 1 |
| Brumback, RA | 1 |
1 trial available for desipramine and Congenital Myotonic Dystrophy
| Article | Year |
|---|---|
A pilot controlled study of the use of imipramine to reduce myotonia.
Topics: Adult; Desipramine; Double-Blind Method; Drug Evaluation; Female; Humans; Imipramine; Male; Middle A | 1989 |